LYPLA2 inhibition alleviates hepatic sinusoidal obstruction syndrome by suppressing pSTAT3-dependent HSP60 transcription
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2027-03 · 1873 (3) · 168525
DOI: 10.1016/j.bbadis.2026.168525 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2027-03. Verfasst von Xiaofei Ren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Electronic address: yfy114759@fy.ahmu.edu.cn. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Anhui Medical University.
Abstract (Originalsprache)
To investigate the underlying molecular mechanisms involved in the progression of hepatic sinusoidal obstruction syndrome (HSOS) and the mechanisms by which low-molecular-weight heparin (LMWH) alleviates HSOS. Monocrotaline (MCT) was administered to establish rat and cellular models of HSOS. Rats received subcutaneous injections of enoxaparin (EPN; 8 mg/kg) at three time points: 48 h, 24 h, and 30 min prior to MCT administration. Liver tissue protein expression profiles from the Control, MCT, and MCT + EPN groups were subsequently analyzed using proteomics. Lysophospholipase 2 (LYPLA2) inhibitor ML349 (35 mg/kg) was intraperitoneally injected daily for 7 consecutive days before MCT administration. The results showed that LYPLA2 protein level in liver tissues of HSOS rats was increased (log2FC = 1.05, p = 0.047) but decreased by EPN (log2FC = -1.11, p = 0.037). Treatment with LYPLA2 inhibitor ML349 or LYPLA2 knockdown alleviated MCT-induced liver tissues and human hepatic sinus endothelial cells (HSECs) injury by reducing cell apoptosis and inflammation. The underlying mechanism was that LYPLA2 inhibition decreased pSTAT3 level in cytoplasm and nucleus. Meanwhile, LYPLA2 inhibition increased palmitoylation of pSTAT3, which is known to mediate plasma membrane retention of pSTAT3. The decrease of pSTAT3 in nucleus suppressed the transcription of heat shock protein 60 (HSP60). HSP60, a driver of HSOS progression, overexpression reversed the effects caused by ML349 or LYPLA2 knockdown. The observations demonstrate that LYPLA2 inhibition alleviates MCT-induced liver injury by inhibiting pSTAT3-mediated HSP60 transcription, suggesting that ML349 may confer preventive protection against HSOS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Electronic address: yfy114759@fy.ahmu.edu.cn.
- Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- First Clinical Medical College (First Affiliated Hospital), Anhui Medical University, Hefei, China.
Förderung
- Anhui Medical University
Zitieren
APA
Ren, X., Zhang, H., Hong, R., & Du, X. (2027). LYPLA2 inhibition alleviates hepatic sinusoidal obstruction syndrome by suppressing pSTAT3-dependent HSP60 transcription. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1873(3), 168525. https://doi.org/10.1016/j.bbadis.2026.168525
Vancouver
Ren X, Zhang H, Hong R, Du X. LYPLA2 inhibition alleviates hepatic sinusoidal obstruction syndrome by suppressing pSTAT3-dependent HSP60 transcription. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2027;1873(3):168525. doi:10.1016/j.bbadis.2026.168525
BibTeX
@article{Ren2027,
author = {Ren, Xiaofei and Zhang, Haiwang and Hong, Rutao and Du, Xinyan},
title = {LYPLA2 inhibition alleviates hepatic sinusoidal obstruction syndrome by suppressing pSTAT3-dependent HSP60 transcription},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2027},
volume = {1873},
number = {3},
pages = {168525},
doi = {10.1016/j.bbadis.2026.168525}
}
EUVIMED